Macomics Limited

Less than a week to go to vote for Macomics in the @OneNucleus #BioNewsRound #awards 2023 for the news of our deal with @Ono_Pharma_pr - voting is just one click away app.sli.do/event/xBbQ94pZ…

We are thrilled to be shortlisted in this year's BioNewsRound awards. Voting is now open - click here lnkd.in/eSt_TMxN

Delighted to announce that Macomics has been seleted as a finalist for the ON Helix BioNewsRound Award 2023 linkedin.com/posts/one-nucl…

Passionate about developing novel therapies targeting tumour-associated macrophages, he leaves a huge legacy to the cancer research community and to the world of macrophage biology.

With great sadness we announce the passing of our Founder, Director and Adviser, Professor Jeff W. Pollard, on 1 May 2023. He died peacefully at home after struggling against cancer.

Our Co-Founder and VP Immunology, @CassettaLuca is speaking at #ImmunoUK by @OGConferences on 28-29 March. Luca will share our precision medicine approach which modulates #macrophage biology as an innovative #cancer treatment. Find out more: oxfordglobal.co.uk/immuno-series-…

Congratulations to our talented runners Alicia Poindron, Chantell Payton, Amber Ngo, Moritz Haneklaus, and Krzysztof Wicher who completed the #Cambridge Chariots of Fire run this weekend in aid of Arthur Rank Hospice👏 🥳 Donate here justgiving.com/fundraising/ma…

Summer is over, conference season is here. We’ll be attending a number of business & scientific conferences in the coming months: read full list here macomics.com/2022/09/05/mac…. Reach out if you’d like to meet us for an update on our progress #macrophage #drugdiscovery #Immunology

Lisa Seymour (AIOSH) joins from Sanger Institute bringing 18 years experience in technical and admin roles. A graduate from Cambridge University, Member of IOSH & the Royal Society of Biology with NEBOSH general Certificate in Occupational Health & Safety.

Dr Cui specialises in bioinformatic analysis of large-scale multi-omics data. He is building our bioinformatic engine to deepen our understanding of biology of human macrophages. Past experience Apitope, Cardiff University, the University of Cambridge, University of Bristol.

We are delighted to welcome 3 new team member to our #Cambridgeshire and #Edinburgh sites. In our R&D team, Dr Thomas Crozier joins as a Senior Scientist & Dr Yuxin Cui as Senior Bioinformatician. Ms. Lisa Seymour joining as Operations Manager and Health & Safety Officer.

Our co-founder Prof. Jeffery Pollard has been named on the annual Highly Cited Researchers™ 2021 list from @ClarivateAG. His ground-breaking research demonstrates the role of #macrophages in disease. #congratulations #HighlyCited2021 #immunotherapy #cancer

#Congratulations - our co-founder and VP Immunology, Dr @CassettaLuca has been honoured with the @sitcancer ‘Best Immunotherapy Biomarkers Paper Award’ for this publication jitc.bmj.com/content/8/2/e0… #SITC21 #Immunotherapy #Cancer

Our Co-Founder and VP Immunology, @CassettaLuca will be presenting at the ImmunoUK: In person by @OGConferences on #macrophage biology. We’re delighted to be able to present in person once again. To find out more about the event: bit.ly/3p5w9JV

Welcome to our new R&D team members #MoritzHaneklaus #CarmenRodriguezSeoane #ChantellPayton #ConorPoland #SadieKemp. Full release here (macomics.com/wp-content/upl…). #lifesciences #oncology #cancer #drugdiscovery #appointment #expansion #Cambridge #macrophage #Edinburgh

Our leadership team is expanded with the appointment of Carola Ries who joins as Chief Scientific Officer after 16 years at @Roche, to lead our macrophage-based therapeutics R&D. Welcome. Full release including our £4.24m follow-on financing (macomics.com/2021/07/29/mac…).

Pleased to announce £4.24m follow-on financing. Existing investors Epidarex Capital, who led the round, & Scottish Enterprise, & new investor Caribou Property Limited @ElizabethRoper Full release here (macomics.com/2021/07/29/mac…). #Edinburgh #Cambridge #drugdiscovery #Biotechnology